

# Top 10 Drug Delivery Technologies Market

<https://marketpublishers.com/r/T752159A9B2EN.html>

Date: February 2011

Pages: 388

Price: US\$ 5,650.00 (Single User License)

ID: T752159A9B2EN

## Abstracts

### Report Description:

#### STUDY GOALS AND OBJECTIVES

To define and measure drug delivery market and its various sub-segments with respect to types of systems, by mode of drug delivery, by therapeutics and others.

To identify major drivers and restraints of the market

To evaluate comprehensively all drug delivery technologies and benchmark them against various parameters to identify top ten technologies.

To identify and analyze comprehensively market structure with respect to the factors influencing market growth and industry specific challenges.

To analyze trends and forecasts of drug delivery market and its segments

To identify major stakeholders in the market and draw a competitive landscape for market leaders for each of the drug delivery technology market.

To analyze opportunities in the market for stakeholders

To strategically analyze micro markets with respect to their individual growth trends, future prospects and contribution to the total market

To understand regulatory framework, design criteria, pricing issues, threat from alternative methods available in the market.

To analyze and forecast revenues of market segments with respect to geographies (North America, Europe, Asia and Rest of the World

To provide comprehensive analysis of top players in the drug delivery technology market.

To effectively scope out and justify evaluation and provide sufficient basis of ranking top ten drug delivery technologies.

## **REASONS FOR DOING THE STUDY**

More than 25% of the marketed drugs fail to provide expected commercial returns due to drug distribution and absorption levels within the body (pharmacokinetics) therefore signifying the importance of drug delivery systems. Rapid enhancements in drug discovery technologies have led to developments in proteomics and genomics and had a greater impact on drug delivery technology market. The changing market trends, with quick cycle of innovations have compelled market participants to clearly understand changing dynamics and focus on emerging technology and enhance market positions in terms of revenues, growth and geographical presence.

## **SCOPE AND FORMAT**

The report intensively evaluates drug delivery technologies with respect to revenues, growth, therapeutic areas, patents registered and industry focus to arrive at top 10 drug delivery technologies. The key drug delivery technologies discussed in the report are:

Oral drug delivery technologies

Injectable drug delivery technologies

Pulmonary drug delivery technologies

Transdermal drug delivery technologies

Other drug delivery technologies

The report also focuses on the emerging drug delivery technologies and mechanisms.

## **INTENDED AUDIENCES**

Drug delivery technology – manufacturers, suppliers and dealers

Pharmaceutical and biotech companies

Healthcare providers

Potential investors in the drug delivery technology market

## **INFORMATION SOURCES**

Each of the section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for various geographic regions covering sub segments and micro markets. In addition the report also provides 40 companies. Key market developments will be sourced from the top companies that are profiled. Secondary research will progress through both paid and unpaid sources. We will conduct primary research to provide in-depth understanding of the market.

## Contents

### EXECUTIVE SUMMARY

OBJECTIVE  
MARKET SCENARIO  
EMERGING TECHNOLOGIES

### 1 INTRODUCTION

1.1 KEY TAKE-AWAYS  
1.2 REPORT DESCRIPTION  
1.3 MARKETS COVERED  
1.4 STAKEHOLDERS  
1.5 RESEARCH METHODOLOGY

### 2 SUMMARY

### 3 MARKET OVERVIEW

3.1 INTRODUCTION  
3.2 ROLE OF DRUG DELIVERY IN DRUG LIFE CYCLE  
3.3 STAKEHOLDERS  
3.4 CHALLENGES  
    3.4.1 GOVERNMENT REGULATIONS  
    3.4.2 PRICING PRESSURE, REIMBURSEMENTS, & THIRD-PARTY DEPENDENCE  
    3.4.3 PATENT LITIGATIONS  
    3.4.4 PHARMA COMPANIES DEVELOP IN-HOUSE DRUG DELIVERY CAPABILITIES  
3.5 CONVENIENCE IS THE KEY FOR COMMERCIAL SUCCESS OF FUTURE DRUGS  
3.6 PATENT ANALYSIS

### 4 MARKET DYNAMICS

4.1 INTRODUCTION  
4.2 DRIVERS  
    4.2.1 PATENT EXPIRATION OF DRUGS  
    4.2.2 NEED FOR EFFECTIVE DELIVERY OF NOVEL PHARMACEUTICALS &

## BIOPHARMACEUTICALS

### 4.2.3 REDUCE ATTRITION RATES & FASTER DRUG DISCOVERY/DEVELOPMENT PROCESSES

### 4.2.4 EXPANDED APPLICATIONS OF UNCONVENTIONAL MODES OF DRUG DELIVERY

### 4.2.5 INNOVATIONS IN DRUG DELIVERY TECHNOLOGIES

## 4.3 RESTRAINTS

### 4.3.1 DRUG FAILURES RAISE CONCERNS ON ROI

### 4.3.2 U.S. HEALTHCARE REFORMS

## 4.4 OPPORTUNITIES

### 4.4.1 HOME-CARE DRUG DELIVERY DEVICES & SELF-ADMINISTRATION

### 4.4.2 NICHE THERAPEUTIC AREAS

### 4.4.3 WELLNESS PRODUCTS

## 5 CONTROLLED RELEASE TECHNOLOGY

### 5.1 INTRODUCTION

#### 5.1.1 KEY MARKET PLAYERS

### 5.2 DRIVERS

#### 5.2.1 CONTROLLED RELEASE FORMULATIONS IN KEY THERAPEUTIC AREAS

#### 5.2.2 ONCE-A-DAY FORMULATIONS

#### 5.2.3 COST EFFECTIVE

### 5.3 RESTRAINTS

#### 5.3.1 LIMITED NUMBER OF MATERIALS

#### 5.3.2 TECHNICAL BARRIERS

### 5.4 OPPORTUNITIES

#### 5.4.1 PARTICULATE & CHRONOPHARMACOKINETIC SYSTEMS

#### 5.4.2 MUCOADHESIVE DRUG DELIVERY

### 5.5 BIODEGRADABLE POLYMERS

### 5.6 HYDROGEL

### 5.7 MULTIPARTICULATE BEAD SYSTEMS

### 5.8 ION EXCHANGE RESINS

### 5.9 OSMOTIC PRESSURE CONTROLLED SYSTEMS

### 5.10 DISSOLUTION/DIFFUSION SYSTEMS

#### 5.10.1 MATRIX SYSTEMS

#### 5.10.2 RESERVOIR SYSTEMS

### 5.11 OTHERS

### 5.12 REGULATORY ENVIRONMENT

### 5.13 CONTROLLED RELEASE VS IMMEDIATE RELEASE FORMULATIONS

5.14 INNOVATIONS IN CONTROLLED RELEASE TECHNOLOGIES

5.15 BURNING ISSUES

5.16 WINNING IMPERATIVES

5.17 COMPETITIVE DEVELOPMENTS

## **6 TARGETED DELIVERY**

6.1 INTRODUCTION

6.1.1 KEY MARKET PLAYERS

6.2 DRIVERS & RESTRAINTS

6.2.1 INCREASED DEMAND FOR TREATMENT OF CANCEROUS TUMORS

6.2.2 LACK OF TARGETED DRUG DELIVERY TECHNOLOGIES FOR TREATMENT OF BRAIN TUMOR

6.2.3 HIGH COST OF TARGETED ANTIBODY-BASED CANCER THERAPEUTICS

6.3 OPPORTUNITY

6.3.1 NOVEL TARGETED DRUG DELIVERY SYSTEMS

6.4 TARGETING LIGANDS

6.4.1.1 Antibody fragment drug conjugate delivery

6.4.1.2 Antibody directed enzyme prodrug targeted delivery

6.4.1.3 Peptide-targeted delivery

6.4.1.4 Small molecule conjugate delivery

6.4.1.5 Others

6.5 NON-BIOLOGICAL TARGETING PLATFORMS

6.6 CURRENTLY MARKETED TARGETED THERAPIES

6.7 IMPACT OF TARGETED DRUG DELIVERY IN CANCER & OTHER CHRONIC CONDITIONS

6.8 INNOVATIONS

6.9 INDUSTRY INSIGHTS

6.10 WINNING IMPERATIVES

## **7 ENCAPSULATION TECHNOLOGIES**

7.1 INTRODUCTION

7.1.1 KEY MARKET PLAYERS

7.2 DRIVERS & RESTRAINTS

7.2.1 ENHANCED BIOAVAILABILITY

7.2.2 EXTENSIVE USAGE IN TASTE MASKING & FASTER DISSOLVING PILLS

7.2.3 ECONOMICALLY FEASIBLE

7.2.4 RELUCTANCE IN INVESTING IN NOVEL TECHNOLOGIES

## 7.3 OPPORTUNITY

### 7.3.1 SOPHISTICATED MICROENCAPSULATION SYSTEMS

## 7.4 TASTE MASKING

## 7.5 FAST DISSOLVING PILLS

## 7.6 EVOLUTION OF ENCAPSULATION TECHNOLOGIES

## 7.7 APPLICATION OF ENCAPSULATION TECHNOLOGIES IN DIFFERENT MODES OF DRUG DELIVERY

## 7.8 INDUSTRY INSIGHTS

## 7.9 WINNING IMPERATIVES

## 7.10 COMPETITIVE DEVELOPMENTS

# 8 TOPICAL FORMULATIONS

## 8.1 INTRODUCTION

### 8.1.1 KEY MARKET PLAYERS

## 8.2 DRIVERS & RESTRAINTS

### 8.2.1 BURN & WOUND TREATMENT

### 8.2.2 BYPASSING FIRST PASS EFFECT

### 8.2.3 CONVENIENCE FACTOR

### 8.2.4 USAGE IN LIMITED THERAPEUTIC AREAS

## 8.3 OPPORTUNITY

### 8.3.1 TECHNOLOGY ADVANCEMENTS EXPAND APPLICATIONS

## 8.4 GEL TECHNOLOGY

## 8.5 MICROEMULSIONS

## 8.6 BIPHASIC SYSTEM

## 8.7 OTHERS

## 8.8 INDUSTRY INSIGHTS

## 8.9 WINNING IMPERATIVES

## 8.10 COMPETITIVE DEVELOPMENTS

# 9 INHALER TECHNOLOGY

## 9.1 INTRODUCTION

### 9.1.1 KEY MARKET PLAYERS

## 9.2 DRIVERS & RESTRAINTS

### 9.2.1 INCREASE IN ASTHMA & COPD PATIENTS

## 9.2.2 TECHNOLOGICAL ADVANCEMENTS IN AEROSOL FORMULATION AND DEVICE DESIGN

### 9.2.3 EASE OF USE, SELF-ADMINISTRATION, & PAINLESS DRUG DELIVERY

- 9.2.4 FAILURE OF EXUBERA
- 9.3 OPPORTUNITY
  - 9.3.1 APPLICATION IN NON-RESPIRATORY CONDITIONS
- 9.4 DRY POWDER INHALERS
- 9.5 METERED DOSE INHALERS
- 9.6 NEBULIZERS
- 9.7 EVOLUTION OF INHALER DEVICES
- 9.8 REGULATORY ENVIRONMENT
- 9.9 TECHNOLOGY INNOVATIONS
- 9.10 INDUSTRY INSIGHTS
- 9.11 WINNING IMPERATIVES
- 9.12 COMPETITIVE DEVELOPMENTS

## **10 INJECTABLE DRUG DELIVERY**

- 10.1 INJECTION DEVICES
  - 10.1.1 KEY MARKET DYNAMICS
    - 10.1.1.1 Drivers
      - 10.1.1.1.1 Growth of self-administration therapies
      - 10.1.1.1.2 Needle-stick legislation
      - 10.1.1.1.3 Increasing acceptance by physicians and patients
      - 10.1.1.1.4 Reducing cost of treatment
    - 10.1.1.2 Restraints
      - 10.1.1.2.1 Need of new drug formulation
    - 10.1.1.3 Opportunities
      - 10.1.1.3.1 Product differentiation through added functional features
      - 10.1.1.3.2 Expansion to new areas
  - 10.2 CRITERIA FOR SELECTION OF INJECTABLE DEVICE
  - 10.3 KEY DEVELOPMENTS
    - 10.3.1 DEVELOPMENT OF MICRONEEDLES
    - 10.3.2 DEVELOPMENT OF NEEDLE-FREE DEVICES FOR ADMINISTRATION OF POWDERED DRUGS
  - 10.4 CONVENTIONAL INJECTABLES
  - 10.5 PREFILLED SYRINGES (PFS)
    - 10.5.1 KEY MARKET DYNAMICS
      - 10.5.1.1 Drivers
        - 10.5.1.1.1 Growing market for self-injection devices
        - 10.5.1.1.2 Wastage control and cost reduction through less overfill
        - 10.5.1.1.3 Ease of manufacture & convenient usability



- 10.5.1.2 Restraints
  - 10.5.1.2.1 Threat from needle-free devices
  - 10.5.1.2.2 Protecting product quality
- 10.5.2 GLASS PFS
- 10.5.3 PLASTIC PFS
- 10.6 SELF INJECTION DEVICES
  - 10.6.1 AUTO INJECTORS
    - 10.6.1.1 Reusable auto-injectors
    - 10.6.1.2 Disposable auto-injectors
  - 10.6.2 PEN INJECTORS
    - 10.6.2.1 Reusable pen injectors
    - 10.6.2.2 Disposable pen injectors
  - 10.6.3 NEEDLE-FREE INJECTORS (NFI)
    - 10.6.3.1 Reusable NFIs
    - 10.6.3.2 Disposable NFIs
- 10.7 OTHERS

## **11 TRANSDERMAL PATCH**

- 11.1 INTRODUCTION
  - 11.1.1 KEY MARKET PLAYERS
- 11.2 DRIVERS
  - 11.2.1 REDUCED SIDE EFFECTS & BETTER EFFICACY
  - 11.2.2 CONVENIENT & LESS PAINFUL
- 11.3 RESTRAINTS
  - 11.3.1 RECALL OF DURAGESIC & NEGATIVE PUBLICITY OF ORTHO EVRA PATCH
  - 11.3.2 LOW SKIN PERMEABILITY OF DRUGS
- 11.4 OPPORTUNITIES
  - 11.4.1 NEW PRODUCTS
    - 11.4.1.1 Contraceptive patch
    - 11.4.1.2 Pain management patch
    - 11.4.1.3 Estrogen/hormone replacement patch
- 11.5 INDUSTRY INSIGHTS
- 11.6 WINNING IMPERATIVES
- 11.7 COMPETITIVE DEVELOPMENTS

## **12 IMPLANTABLE DRUG DELIVERY**

## 12.1 INTRODUCTION

## 12.2 DRIVERS & RESTRAINTS

### 12.2.1 SELECTIVE DRUG DELIVERY & LOW AMOUNT OF ACTIVE DRUG INGREDIENT

#### 12.2.2 DOSING ADMINISTRATION NOT REQUIRED

#### 12.2.3 INCONVENIENCE

## 12.3 OPPORTUNITY

### 12.3.1 TECHNOLOGICAL ADVANCES ENHANCE APPLICATIONS

## 12.4 CORONARY (DRUG ELUTING) STENTS

## 12.5 IMPLANTABLE INFUSION PUMPS

## 12.6 OCULAR IMPLANTS & OTHERS

## 12.7 INDUSTRY INSIGHTS

## 12.8 WINNING IMPERATIVES

# 13 LIPOSOMAL DRUG DELIVERY

## 13.1 INTRODUCTION

## 13.2 DRIVERS & RESTRAINTS

### 13.2.1 ENHANCED USAGE IN CANCER

### 13.2.2 EASY MANUFACTURING PROCEDURE & COST EFFECTIVENESS

### 13.2.3 SIDE EFFECTS

## 13.3 OPPORTUNITY

### 13.3.1 NANOSCALE LIPOSOME DRUG DELIVERY

## 13.4 INDUSTRY INSIGHTS

## 13.5 WINNING IMPERATIVES

## 13.6 COMPETITIVE DEVELOPMENTS

# 14 PEGYLATION TECHNOLOGIES

## 14.1 INTRODUCTION

## 14.2 DRIVERS & RESTRAINTS

### 14.2.1 BIOLOGICAL DRUGS

### 14.2.2 ENHANCED PHARMACOKINETIC PROPERTIES & REDUCED DOSAGE

### 14.2.3 EXPENSIVE MANUFACTURING PROCEDURE

## 14.3 OPPORTUNITY

### 14.3.1 TECHNOLOGICAL ADVANCES

## 14.4 INDUSTRY INSIGHTS

## 14.5 WINNING IMPERATIVES

## **15 COMPETITIVE LANDSCAPE**

### 15.1 INTRODUCTION

### 15.2 ANALYSIS OF TOP PLAYERS

#### 15.2.1 STRATEGY

#### 15.2.2 INJECTABLE DRUG DELIVERY DEVICES MARKET SHARE

##### 15.2.2.1 Top injectable drug delivery device companies & revenues, by segment

### 15.3 WINNING IMPERATIVES

#### 15.3.1 ALLIANCES

#### 15.3.2 POSITIONING OF DRUG DELIVERY TECHNOLOGY EARLY IN DRUG DISCOVERY

#### 15.3.3 SHIFT FROM PURE DRUG DELIVERY TOWARD SPECIALTY PHARMACEUTICALS

### 15.4 STRATEGIC RECOMMENDATIONS

## **16 GEOGRAPHIC ANALYSIS**

### 16.1 INTRODUCTION

### 16.2 NORTH AMERICA

### 16.3 EUROPE

### 16.4 ASIA

### 16.5 REST OF THE WORLD (ROW)

### 16.6 DECISION SUPPORT DATABASE

## **17 COMPANY PROFILES**

### 17.1 3M COMPANY

#### 17.1.1 OVERVIEW

#### 17.1.2 FINANCIALS

#### 17.1.3 PRODUCTS & SERVICES

#### 17.1.4 STRATEGY

#### 17.1.5 DEVELOPMENTS

### 17.2 ALKERMES, INC

#### 17.2.1 OVERVIEW

#### 17.2.2 FINANCIALS

#### 17.2.3 PRODUCTS & SERVICES

#### 17.2.4 STRATEGY

#### 17.2.5 DEVELOPMENTS

### 17.3 ALTEA THERAPEUTICS INC.

- 17.3.1 OVERVIEW
- 17.3.2 PRODUCTS & SERVICES
- 17.3.3 STRATEGY
- 17.3.4 DEVELOPMENTS
- 17.4 ANTARES PHARMA INC.
  - 17.4.1 OVERVIEW
  - 17.4.2 FINANCIALS
  - 17.4.3 PRODUCTS & SERVICES
  - 17.4.4 STRATEGY
  - 17.4.5 DEVELOPMENTS
- 17.5 A.P. PHARMA, INC.
  - 17.5.1 OVERVIEW
  - 17.5.2 FINANCIALS
  - 17.5.3 PRODUCTS & SERVICES
  - 17.5.4 STRATEGY
  - 17.5.5 DEVELOPMENTS
- 17.6 APPLIED PHARMA
  - 17.6.1 OVERVIEW
  - 17.6.2 PRODUCTS & SERVICES
  - 17.6.3 STRATEGY
  - 17.6.4 DEVELOPMENTS
- 17.7 ARADIGM CORPORATION
  - 17.7.1 OVERVIEW
  - 17.7.2 FINANCIALS
  - 17.7.3 PRODUCTS & SERVICES
  - 17.7.4 STRATEGY
  - 17.7.5 DEVELOPMENTS
- 17.8 BAXTER BIOPHARMA
  - 17.8.1 OVERVIEW
  - 17.8.2 PRODUCTS & SERVICES
  - 17.8.3 FINANCIALS
  - 17.8.4 STRATEGY
  - 17.8.5 DEVELOPMENTS
- 17.9 BECTON, DICKINSON AND COMPANY
  - 17.9.1 OVERVIEW
  - 17.9.2 PRODUCT & SERVICES
  - 17.9.3 FINANCIALS
  - 17.9.4 STRATEGY
  - 17.9.5 DEVELOPMENTS

**17.10 BIOJECT INC.**

17.10.1 OVERVIEW

17.10.2 FINANCIALS

17.10.3 PRODUCTS &amp; SERVICES

17.10.4 STRATEGY

17.10.5 DEVELOPMENTS

**17.11 BIOVAIL CORPORATION (VALEANT PHARMACEUTICALS INTERNATIONAL INC.)**

17.11.1 OVERVIEW

17.11.2 PRODUCTS &amp; SERVICES

17.11.3 FINANCIALS

17.11.4 STRATEGY

17.11.5 DEVELOPMENTS

**17.12 CIMA LABS INC.**

17.12.1 OVERVIEW

17.12.2 PRODUCTS &amp; SERVICES

17.12.3 STRATEGY

17.12.4 DEVELOPMENTS

**17.13 ELAN CORPORATION PLC.**

17.13.1 OVERVIEW

17.13.2 FINANCIALS

17.13.3 PRODUCTS &amp; SERVICES

17.13.4 STRATEGY

17.13.5 DEVELOPMENTS

**17.14 ENDO PHARMACEUTICALS**

17.14.1 OVERVIEW

17.14.2 FINANCIALS

17.14.3 PRODUCTS &amp; SERVICES

17.14.4 STRATEGY

17.14.5 DEVELOPMENTS

**17.15 EURAND PHARMACEUTICALS**

17.15.1 OVERVIEW

17.15.2 FINANCIALS

17.15.3 PRODUCTS &amp; SERVICES

17.15.4 STRATEGY

17.15.5 DEVELOPMENTS

**17.16 FLAMEL TECHNOLOGIES, INC**

17.16.1 OVERVIEW

17.16.2 FINANCIALS

- 17.16.3 PRODUCTS & SERVICES
- 17.16.4 STRATEGY
- 17.16.5 DEVELOPMENTS
- 17.17 JOHNSON & JOHNSON LTD.
  - 17.17.1 OVERVIEW
  - 17.17.2 FINANCIALS
  - 17.17.3 PRODUCTS & SERVICES
  - 17.17.4 STRATEGY
  - 17.17.5 DEVELOPMENTS
- 17.18 KV PHARMACEUTICAL
  - 17.18.1 OVERVIEW
  - 17.18.2 FINANCIALS
  - 17.18.3 PRODUCTS & SERVICES
  - 17.18.4 STRATEGY
  - 17.18.5 DEVELOPMENTS
- 17.19 LABOPHARM INC.
  - 17.19.1 OVERVIEW
  - 17.19.2 FINANCIALS
  - 17.19.3 PRODUCTS & SERVICES
  - 17.19.4 STRATEGY
  - 17.19.5 DEVELOPMENTS
- 17.20 NANOPASS TECHNOLOGIES LTD.
  - 17.20.1 OVERVIEW
  - 17.20.2 PRODUCTS & SERVICES
  - 17.20.3 STRATEGY
  - 17.20.4 DEVELOPMENTS
- 17.21 NEKTAR THERAPEUTICS
  - 17.21.1 OVERVIEW
  - 17.21.2 FINANCIALS
  - 17.21.3 PRODUCTS & SERVICES
  - 17.21.4 STRATEGY
  - 17.21.5 DEVELOPMENTS
- 17.22 QLT INC.
  - 17.22.1 OVERVIEW
  - 17.22.2 FINANCIALS
  - 17.22.3 PRODUCTS & SERVICES
  - 17.22.4 STRATEGY
  - 17.22.5 DEVELOPMENTS
- 17.23 SKYEPHARMA PLC.

- 17.23.1 OVERVIEW
- 17.23.2 FINANCIALS
- 17.23.3 PRODUCTS & SERVICES
- 17.23.4 STRATEGY
- 17.23.5 DEVELOPMENTS
- 17.24 SURMODICS, INC.
  - 17.24.1 OVERVIEW
  - 17.24.2 PRODUCTS & SERVICES
  - 17.24.3 FINANCIALS
  - 17.24.4 STRATEGY
  - 17.24.5 DEVELOPMENTS
- 17.25 VECTURA GROUP PLC
  - 17.25.1 OVERVIEW
  - 17.25.2 FINANCIALS
  - 17.25.3 PRODUCTS & SERVICES
  - 17.25.4 STRATEGY
  - 17.25.5 DEVELOPMENTS
- 17.26 YPSOMED HOLDING AG
  - 17.26.1 OVERVIEW
  - 17.26.2 FINANCIALS
  - 17.26.3 PRODUCTS & SERVICES
  - 17.26.4 STRATEGY
  - 17.26.5 DEVELOPMENTS
- 17.27 ZOGENIX, INC.
  - 17.27.1 OVERVIEW
  - 17.27.2 PRODUCTS & SERVICES
  - 17.27.3 STRATEGY
  - 17.27.4 DEVELOPMENTS

## **APPENDIX**

U.S. PATENTS  
EUROPE PATENTS  
JAPAN PATENTS

## List Of Tables

### LIST OF TABLES

- 1 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENTS 2008 – 2015 (\$MILLION)
- 2 DRUGS SET FOR PATENT EXPIRATION (2010 – 2012)
- 3 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
- 4 GLOBAL CONTROLLED RELEASE TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 (\$MILLION)
- 5 GLOBAL CONTROLLED RELEASE TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 6 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
- 7 GLOBAL BIODEGRADABLE POLYMERS MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 8 GLOBAL HYDROGEL MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 9 GLOBAL MULTIPARTICULATE BEAD SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 10 GLOBAL ION EXCHANGE RESINS MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 11 GLOBAL OSMOTIC PRESSURE CONTROLLED SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 12 GLOBAL DISSOLUTION/DIFFUSION SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 13 GLOBAL MATRIX SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 14 GLOBAL RESERVOIR SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 15 GLOBAL OTHER CONTROLLED RELEASE SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 16 GLOBAL TARGETED DELIVERY TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 (\$MILLION)
- 17 GLOBAL TARGETED DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 18 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
- 19 GLOBAL TARGETING LIGANDS MARKET, BY PRODUCTS 2008 – 2015 (\$MILLION)
- 20 GLOBAL TARGETING LIGANDS MARKET, BY PRODUCTS 2008 – 2015 (\$MILLION)
- 21 GLOBAL ANTIBODY FRAGMENT CONJUGATE DELIVERY MARKET, BY



GEOGRAPHY 2008 – 2015 (\$MILLION)

22 GLOBAL ANTIBODY ENZYME DIRECTED PRODRUG DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)

23 GLOBAL PEPTIDE TARGETED DRUG DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)

24 GLOBAL SMALL MOLECULE CONJUGATE DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)

25 GLOBAL OTHER TARGETING LIGANDS BASED DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)

26 GLOBAL NON-BIOLOGICAL TARGETING PLATFORMS MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)

27 GLOBAL ENCAPSULATION TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 (\$MILLION)

28 GLOBAL ENCAPSULATION TECHNOLOGIES MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)

29 IMPACT ANALYSIS OF KEY MARKET DYNAMICS

30 GLOBAL ENCAPSULATION MARKET IN TASTE MASKING, BY GEOGRAPHY 2008 – 2015 (\$MILLION)

31 GLOBAL ENCAPSULATION MARKET IN FAST DISSOLVING, BY GEOGRAPHY 2008 – 2015 (\$MILLION)

32 GLOBAL TOPICAL FORMULATIONS MARKET, BY PRODUCTS 2008 – 2015 (\$MILLION)

33 GLOBAL TOPICAL FORMULATIONS MARKET, BY GEOGRAPHY (2008 – 2015)

34 IMPACT ANALYSIS OF KEY MARKET DYNAMICS

35 GLOBAL GEL TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)

36 GLOBAL MICROEMULSIONS MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)

37 GLOBAL BIPHASIC SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)

38 GLOBAL OTHER TOPICAL FORMULATIONS MARKET, BY GEOGRAPHY 2008 – 2015 (\$ MILLION)

39 GLOBAL INHALER TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 (\$MILLION)

40 GLOBAL INHALER TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)

41 IMPACT ANALYSIS OF KEY MARKET DYNAMICS

42 GLOBAL DRY POWDER INHALERS MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)

- 43 GLOBAL METERED DOSE INHALERS MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 44 GLOBAL NEBULIZERS MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 45 GLOBAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCTS 2008 – 2015 (\$MILLION)
- 46 GLOBAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHY 2008-2015 (\$MILLION)
- 47 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
- 48 GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 49 GLOBAL PREFILLED SYRINGES MARKET, BY PRODUCTS 2008 – 2015 (\$MILLION)
- 50 GLOBAL PREFILLED SYRINGES MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 51 GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCTS 2008 – 2015 (\$MILLION)
- 52 GLOBAL SELF-INJECTION DEVICES MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 53 GLOBAL AUTO INJECTOR MARKET, BY PRODUCTS 2008 – 2015 (\$MILLION)
- 54 GLOBAL AUTO INJECTOR MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 55 GLOBAL PEN INJECTOR MARKET, BY PRODUCTS 2008 – 2015 (\$MILLION)
- 56 GLOBAL PEN INJECTOR MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 57 MAJOR PRODUCTS IN THE NEEDLE FREE TECHNOLOGY
- 58 GLOBAL NEEDLE-FREE INJECTOR MARKET, BY PRODUCTS 2008 – 2015 (\$MILLION)
- 59 GLOBAL TRANSDERMAL PATCH TECHNOLOGY, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 60 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
- 61 GLOBAL IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY PRODUCTS (2008 – 2015)
- 62 GLOBAL IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 63 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
- 64 GLOBAL CORONARY STENTS MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 65 GLOBAL IMPLANTABLE INFUSION PUMPS MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 66 GLOBAL OCULAR IMPLANTS & OTHERS MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)

- 67 GLOBAL LIPOSOMAL DRUG DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 68 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
- 69 GLOBAL PEGYLATION TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 (\$MILLION)
- 70 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
- 71 REVENUE ANALYSIS (2008 – 2009)
- 72 ELAN TOTAL REVENUES BY DRUG (2008 – 2010)
- 73 ALKERMES TOTAL REVENUES, BY DRUG (2008 – 2010)
- 74 R&D EXPENDITURE (2008 – 2009)
- 75 ELAN'S PIPELINE DRUGS
- 76 BIOVAIL'S PIPELINE DRUGS
- 77 ALKERMES'S PIPELINE DRUGS
- 78 NEKTAR'S PIPELINE DRUGS
- 79 SKYE PHARMA'S PIPELINE DRUGS
- 80 TOP COMPANIES & THEIR STRATEGIES
- 81 BECTON DICKINSON – TOTAL REVENUES, BY SEGMENT (\$MILLION)
- 82 BAXTER BIOPHARMA REVENUES, BY SEGMENT
- 83 YPSOMED - TOTAL REVENUES, BY SEGMENT (\$MILLION)
- 84 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY REGION (2008 – 2015)
- 85 NORTH AMERICAN TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT
- 86 EUROPEAN TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT
- 87 ASIAN TOP 10 DRUG DELIVERY TECHNOLOGIES
- 88 REST OF THE WORLD TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET
- 89 MULTIPLE SCLEROSIS PREVALENCE, BY GEOGRAPHY (2009)
- 90 OSTEOPOROSIS PREVALENCE, BY GEOGRAPHY (2009)
- 91 DIABETES PREVALENCE, BY GEOGRAPHY (2009)
- 92 CANCER PREVALENCE, BY GEOGRAPHY (2009)
- 93 RHEUMATOID ARTHRITIS PREVALENCE, BY GEOGRAPHY (2009)
- 94 ANEMIA PREVALENCE, BY GEOGRAPHY (2009)
- 95 HEPATITIS-C PREVALENCE, BY GEOGRAPHY (2009)
- 96 CROHN'S DISEASE PREVALENCE, BY GEOGRAPHY (2009)
- 97 PSORIASIS PREVALENCE, BY GEOGRAPHY (2009)
- 98 TOTAL REVENUES & R&D EXPENDITURE
- 99 TOTAL REVENUES, BY GEOGRAPHY
- 100 TOTAL REVENUES (2006 – 2010)
- 101 SEGMENT SPECIFIC REVENUES (\$MILLION)
- 102 TOTAL REVENUES & R&D EXPENDITURE (\$MILLION)

- 103 TOTAL REVENUES, BY GEOGRAPHY
- 104 REVENUES, BY SEGMENTS
- 105 TOTAL REVENUES & NET INCOME (\$MILLION)
- 106 TOTAL REVENUES (2007 – 2009)
- 107 BAXTER BIOPHARMA – TOTAL REVENUES & R&D EXPENSES (\$MILLION)
- 108 BAXTER BIOPHARMA – TOTAL REVENUES, BY GEOGRAPHY (\$MILLION)
- 109 BAXTER BIOPHARMA – TOTAL REVENUES, BY SEGMENTS (\$MILLION)
- 110 BAXTER BIOPHARMA – TOTAL REVENUES FOR MEDICATION DELIVERY, BY SEGMENTS (\$MILLION)
- 111 BECTON DICKINSON – TOTAL REVENUES & R&D EXPENDITURE (\$MILLION)
- 112 BECTON DICKINSON – TOTAL REVENUES, BY GEOGRAPHY (\$MILLION)
- 113 BECTON DICKINSON – TOTAL REVENUES, BY SEGMENTS (\$MILLION)
- 114 BECTON DICKINSON – TOTAL REVENUES FOR MEDICAL SURGICAL SYSTEMS, BY SEGMENTS (\$MILLION)
- 115 TOTAL REVENUES & R&D EXPENDITURE
- 116 REVENUES, BY SEGMENTS (\$MILLION)
- 117 TOTAL REVENUES & R&D EXPENDITURE (\$MILLION)
- 118 U.S REVENUES OF BIOVAIL, BY PRODUCTS (\$MILLION)
- 119 TOTAL PRODUCT REVENUES OF BIOVAIL PHARMACEUTICALS CANADA
- 120 TOTAL REVENUES & R&D EXPENDITURE
- 121 REVENUES, BY PRODUCTS
- 122 TOTAL REVENUES & R&D EXPENDITURE
- 123 TOTAL REVENUES & R&D EXPENDITURE (\$MILLION)
- 124 PRODUCT SALES, BY THERAPEUTIC AREA
- 125 REVENUES & R&D EXPENDITURE
- 126 TOTAL REVENUES & R&D EXPENDITURE
- 127 REVENUES, BY BUSINESS SEGMENTS
- 128 REVENUES, BY PRODUCTS
- 129 REVENUES, BY GEOGRAPHY (\$MILLION)
- 130 TOTAL REVENUES & EXPENDITURE
- 131 TOTAL REVENUES & R&D EXPENDITURE
- 132 NEKTAR – TOTAL REVENUES & R&D EXPENSES
- 133 NEKTAR – TOTAL REVENUES, BY GEOGRAPHY (\$MILLION)
- 134 QLT – TOTAL REVENUES & R&D EXPENSES (\$MILLION)
- 135 QLT – TOTAL REVENUES, BY GEOGRAPHY (\$MILLION)
- 136 TOTAL REVENUES & R&D EXPENSES (\$MILLION)
- 137 SURMODICS INC. – TOTAL REVENUES & R&D EXPENSES (\$MILLION)
- 138 SURMODICS INC. – TOTAL REVENUES, BY GEOGRAPHY (\$MILLION)
- 139 SURMODICS INC. – TOTAL REVENUES, BY SEGMENTS (\$MILLION)

140 TOTAL REVENUES & R&D EXPENDITURE

141 YPSOMED - TOTAL REVENUES & R&D EXPENSES (\$MILLION)

142 YPSOMED - TOTAL REVENUES, BY SEGMENTS (\$MILLION)

## List Of Figures

### LIST OF FIGURES

- 1 REVENUE ANALYSIS OF THE TOP 10 DRUG DELIVERY TECHNOLOGIES
- 2 TOP 10 DRUG DELIVERY TECHNOLOGIES – MARKET SHARE
- 3 EVOLUTION OF DRUG DELIVERY TECHNOLOGY INDUSTRY
- 4 ROLE OF DRUG DELIVERY TECHNOLOGIES IN A DRUG LIFE CYCLE
- 5 DRUG DELIVERY TECHNOLOGIES AS REVENUE DRIVERS
- 6 DRUG DELIVERY MARKET STAKEHOLDERS
- 7 IMPACT OF MARKET DRIVERS & RESTRAINTS
- 8 COMPARATIVE ANALYSIS OF DRUG DELIVERY TECHNOLOGIES
- 9 PATENT ANALYSIS, BY SEGMENTS (2004 – 2009)
- 10 PATENT ANALYSIS, BY ASSIGNEE (2004 – 2009)
- 11 COMMON REASONS FOR FAILURE OF DRUGS IN DRUG DISCOVERY/  
DEVELOPMENT PROCESS
- 12 EVOLUTION OF CONTROLLED RELEASE TECHNOLOGIES
- 13 CONTROLLED RELEASE VS IMMEDIATE RELEASE
- 14 TARGETED THERAPY TYPES
- 15 EVOLUTION OF ENCAPSULATION TECHNOLOGIES
- 16 ENCAPSULATION APPLICATIONS IN DIFFERENT MODES OF DRUG DELIVERY
- 17 EVOLUTION OF INHALER TECHNOLOGY
- 18 FACTORS AFFECTING SELECTION OF INJECTABLE DEVICE
- 19 COMPETITIVE DEVELOPMENTS (2007 – JUNE 2010)
- 20 COMPETITIVE DEVELOPMENTS, BY SEGMENTS (2007 – JUNE 2010)
- 21 REVENUE ANALYSIS (2008 – 2009)
- 22 CONTROLLED RELEASE, DRUG FORMULATION – MARKET SHARE
- 23 R&D EXPENDITURE (2008 – 2009)
- 24 INJECTABLE DRUG DELIVERY DEVICES, MARKET SHARE
- 25 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET
- 26 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – NORTH AMERICA
- 27 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – EUROPE
- 28 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – ASIA
- 29 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – ROW

## I would like to order

Product name: Top 10 Drug Delivery Technologies Market

Product link: <https://marketpublishers.com/r/T752159A9B2EN.html>

Price: US\$ 5,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T752159A9B2EN.html>